Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Britain Courts Anthropic Amid US Defense Department Dispute 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
RESEARCH TRIANGLE PARK, N.C., May 09, 2017 -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company’s clinical programs at the Bank of America Merrill Lynch Health Care Conference in Las Vegas on Tuesday, May 16, 2017 at 5:00 p.m. Pacific Time.
Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at http://investor.shareholder.com/biocryst/events.cfm.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst has several ongoing development programs: BCX7353 and other second generation oral inhibitors of plasma kallikrein for hereditary angioedema, and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is a potential treatment for filoviruses. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst's first approved product and has received regulatory approval in the U.S., Canada, Japan, Taiwan and Korea. Post-marketing commitment development activities for RAPIVAB are ongoing, as well as activities to support regulatory approvals in other territories. For more information, please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
CONTACT: Thomas Staab, BioCryst Pharmaceuticals, +1-919-859-7910
